|
Abcam Introduces Alexa Fluor® 680/790 Secondary Antibodies for Fluorescent …
SelectScience.net (press release) Abcam plc, a global leader in the supply of innovative protein research tools, announced today it has added Alexa Fluor® 680/790 secondary antibodies for fluorescent western blotting to its existing Alexa Fluor conjugated antibody range. Produced and … |
SA scientists exploring antibodies to combat HIVTimes LIVEA method for developing antibodies with the ability to kill multiple strains of the human immunodeficiency virus (HIV) was announced on Monday by South African scientists working with US researc…
IBNLive |
Antibodies hold promise for effective HIV vaccine
Daily News & Analysis In a path-breaking finding, researchers have discovered how the immune system makes a powerful antibody that blocks HIV infection of cells by targeting the V1V2 site on the virus. It is believed that if a vaccine could elicit potent antibodies to a … SA scientists exploring antibodies to combat HIVTimes LIVE Study of antibody evolution charts course toward HIV vaccineEurekAlert (press release) |
Antibodies hold promise for effective HIV vaccineBusiness StandardIt is believed that if a vaccine could elicit potent antibodies to a specific conserved site in the V1V2 region, then the vaccine could protect people from HIV infection. The V1V2 is a r…
Science Codex |
Clues to curing Aids could live in antibodies
Mail & Guardian Online In a study that was published in the scientific journal, Nature, on Sunday night, South African and American researchers describe how the research team found and identified these antibodies in her blood and then duplicated them by cloning the … Study of antibody evolution charts course toward HIV vaccineMedical Xpress |
|
Investigation Report on China Rituximab Market, 2009-2018
The International News Magazine Reportstack has announced a new market research publication on Investigation Report on China Rituximab Market, 2009-2018. Rituximab (trade names “MabThera” by Roche, “Rituxan” by Genetech) is a chimeric monoclonal antibody against the protein … |
|
Investigation Report on China Rituximab Market, 2009-2018
PR Carbon (press release) FOR IMMEDIATE RELEASE, Illinois – United States – February 28,2014 (PR Carbon):Reportstack has announced a new market research publication on Investigation Report on China Rituximab Market, 2009-2018. Rituximab (trade names “MabThera” by … |
|
China Rituximab Market Investigation Report 2018 Forecasts
The International News Magazine Rituximab (trade names “MabThera” by Roche, “Rituxan” by Genetech) is a chimeric monoclonal antibody against the protein CD20 approved in 1997 to treat tumor. It is very effective and shows good tolerance in the treatment of Bcell lymphoma. As people … |
Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes7thSpace Interactive (press release)Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes. Lysophosphatidic acid (LPA) is a bioactive phospholipid with…
|
Immunomedics extends patent life on therapeutic antibodies
Pharmaceutical Business Review The patent covers all of the company’s therapeutic antibodies, and can also be applied to most other antibodies, permitting a concentrated formulation to be given in low volume (3ml or less) and not requiring a special device. The patent has an … |